Nurix Therapeutics, Inc. (NASDAQ:NRIX) Insider Christine Ring Sells 5,760 Shares

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Christine Ring sold 5,760 shares of the firm’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $20.81, for a total transaction of $119,865.60. Following the completion of the transaction, the insider now directly owns 19,838 shares of the company’s stock, valued at approximately $412,828.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Christine Ring also recently made the following trade(s):

• On Wednesday, June 12th, Christine Ring sold 1,900 shares of Nurix Therapeutics stock. The shares were sold at an average price of $17.01, for a total value of $32,319.00.
• On Wednesday, June 5th, Christine Ring sold 400 shares of Nurix Therapeutics stock. The shares were sold at an average price of $17.00, for a total value of $6,800.00.
• On Monday, June 3rd, Christine Ring sold 1,596 shares of Nurix Therapeutics stock. The stock was sold at an average price of $17.01, for a total value of $27,147.96.

Nurix Therapeutics Price Performance

NASDAQ NRIX traded up $0.04 during trading hours on Monday, reaching $20.91. The company’s stock had a trading volume of 979,247 shares, compared to its average volume of 1,007,004. Nurix Therapeutics, Inc. has a 1-year low of $4.22 and a 1-year high of $22.44. The company’s 50-day moving average is $15.79 and its two-hundred day moving average is $12.89. The firm has a market capitalization of $1.03 billion, a price-to-earnings ratio of -7.86 and a beta of 2.17.

Nurix Therapeutics (NASDAQ:NRIX) last announced its earnings results on Wednesday, April 10th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.80) by $0.04. The business had revenue of $16.59 million for the quarter, compared to analyst estimates of $14.58 million. Nurix Therapeutics had a negative net margin of 178.93% and a negative return on equity of 67.08%. Equities analysts forecast that Nurix Therapeutics, Inc. will post -2.85 EPS for the current fiscal year.

Hedge Funds Weigh In On Nurix Therapeutics

A number of hedge funds have recently made changes to their positions in the company. Redmile Group LLC lifted its stake in Nurix Therapeutics by 37.7% in the 1st quarter. Redmile Group LLC now owns 4,483,016 shares of the company’s stock worth $65,900,000 after purchasing an additional 1,226,497 shares in the last quarter. ARK Investment Management LLC grew its holdings in shares of Nurix Therapeutics by 23.2% in the fourth quarter. ARK Investment Management LLC now owns 3,194,999 shares of the company’s stock valued at $32,972,000 after purchasing an additional 601,952 shares during the period. Affinity Asset Advisors LLC increased its position in Nurix Therapeutics by 176.0% during the fourth quarter. Affinity Asset Advisors LLC now owns 690,112 shares of the company’s stock worth $7,122,000 after purchasing an additional 440,112 shares during the last quarter. Ikarian Capital LLC purchased a new position in Nurix Therapeutics during the first quarter worth about $4,410,000. Finally, Opaleye Management Inc. acquired a new position in Nurix Therapeutics in the 1st quarter valued at about $3,928,000.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Stephens started coverage on shares of Nurix Therapeutics in a research report on Tuesday, May 14th. They set an “overweight” rating and a $20.00 price target for the company. Needham & Company LLC reissued a “buy” rating and set a $31.00 target price on shares of Nurix Therapeutics in a report on Monday, June 17th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $27.00 price target on shares of Nurix Therapeutics in a report on Wednesday, May 15th. Royal Bank of Canada lifted their price objective on Nurix Therapeutics from $23.00 to $26.00 and gave the company an “outperform” rating in a research note on Thursday. Finally, JPMorgan Chase & Co. upped their target price on Nurix Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a research note on Monday, June 17th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $25.10.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.